Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Resveratrol187 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00014 | 35254877 | Arch Physiol Biochem | Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a/SIRT1 axis. | 2022 | Details |
| A00017 | 35252807 | iScience | A network-based computational and experimental framework for repurposing compounds toward the treatment of non-alcoholic fatty liver disease. | 2022 | Details |
| A00095 | 35221291 | J Pharmacol Exp Ther | Resveratrol attenuates HFD-induced hepatic lipotoxicity by up-regulating Bmi-1 expression. | 2022 | Details |
| A00221 | 35178496 | APL Bioeng | Development of resveratrol with thiolated alginate as a supplement to prevent nonalcoholic fatty liver disease (NAFLD). | 2022 | Details |
| A00744 | 34981470 | Adv Exp Med Biol | The Effect of Herbal Medicine and Natural Bioactive Compounds on Plasma Adiponectin: A Clinical Review. | 2021 | Details |
| A00763 | 34977130 | Front Nutr | Sirt1 Promotes the Restoration of Hepatic Progenitor Cell (HPC)-Mediated Liver Fatty Injury in NAFLD Through Activating the Wnt/β-Catenin Signal Pathway. | 2021 | Details |
| A00795 | 34964604 | Biomacromolecules | Construction of Glycogen-Based Nanoparticles Loaded with Resveratrol for the Alleviation of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A00850 | 34948230 | Int J Mol Sci | It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them? | 2021 | Details |
| A00898 | 34935645 | JCI Insight | Maternal Western diet exposure increases periportal fibrosis beginning in utero in nonhuman primate offspring. | 2021 | Details |
| A01702 | 34650394 | Food Nutr Res | Chronic liquid fructose supplementation does not cause liver tumorigenesis but elicits clear sex differences in the metabolic response in Sprague-Dawley rats. | 2021 | Details |
| A01704 | 34649337 | Biomed Pharmacother | Jiangzhi Granule attenuates non-alcoholic steatohepatitis by suppressing TNF/NFκB signaling pathway-a study based on network pharmacology. | 2021 | Details |
| A02178 | 34473313 | Methods Mol Biol | Therapeutic Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Through Inflammatory, Oxidative Stress, Metabolic, and Epigenetic Modifications. | 2022 | Details |
| A02182 | 34470993 | J Toxicol Sci | Resveratrol reverses the programmed high-susceptibility to non-alcoholic fatty liver disease by targeting the hepatic SIRT1-SREBP1c pathway in prenatal ethanol-exposed rat offspring. | 2021 | Details |
| A02254 | 34445644 | Int J Mol Sci | Resveratrol and Quercetin as Regulators of Inflammatory and Purinergic Receptors to Attenuate Liver Damage Associated to Metabolic Syndrome. | 2021 | Details |
| A02474 | 34360538 | Int J Mol Sci | Diabetes Mellitus and Cardiovascular Diseases: Nutraceutical Interventions Related to Caloric Restriction. | 2021 | Details |
| A02598 | 34320173 | Am J Clin Nutr | The effects of resveratrol supplementation in patients with type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease: an umbrella review of meta-analyses of randomized controlled trials. | 2021 | Details |
| A02751 | 34260003 | Neurochem Res | Resveratrol Protects SH-SY5Y Cells Against Oleic Acid-Induced Glucolipid Metabolic Dysfunction and Cell Injuries Via the Wnt/β-Catenin Signalling Pathway. | 2021 | Details |
| A03265 | 34065444 | Nutrients | Gut Microbiota Induced by Pterostilbene and Resveratrol in High-Fat-High-Fructose Fed Rats: Putative Role in Steatohepatitis Onset. | 2021 | Details |
| A03460 | 33992930 | Eur J Med Chem | Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview. | 2021 | Details |
| A03754 | 33877249 | Food Funct | Pterostilbene modifies triglyceride metabolism in hepatic steatosis induced by high-fat high-fructose feeding: a comparison with its analog resveratrol. | 2021 | Details |
| A03796 | 33861449 | Adv Exp Med Biol | Beneficial Effects of Plant-Derived Natural Products on Non-alcoholic Fatty Liver Disease. | 2021 | Details |
| A03797 | 33861444 | Adv Exp Med Biol | Medicinal Plants and Phytochemicals Regulating Insulin Resistance and Glucose Homeostasis in Type 2 Diabetic Patients: A Clinical Review. | 2021 | Details |
| A03970 | 33805912 | Int J Mol Sci | Potential of Nutraceutical Supplementation in the Modulation of White and Brown Fat Tissues in Obesity-Associated Disorders: Role of Inflammatory Signalling. | 2021 | Details |
| A03972 | 33805795 | Nutrients | The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials. | 2021 | Details |
| A04068 | 33771699 | Pharmacol Res | Epigenetics in NAFLD/NASH: Targets and therapy. | 2021 | Details |
| A04097 | 33761646 | Medicine (Baltimore) | The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials. | 2021 | Details |
| A04174 | 33728021 | Oxid Med Cell Longev | Plant-Based Foods and Their Bioactive Compounds on Fatty Liver Disease: Effects, Mechanisms, and Clinical Application. | 2021 | Details |
| A04225 | 33708180 | Front Microbiol | Resveratrol Improves Liver Steatosis and Insulin Resistance in Non-alcoholic Fatty Liver Disease in Association With the Gut Microbiota. | 2021 | Details |
| A04394 | 33636349 | Pharmacol Res | Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. | 2021 | Details |
| A04514 | 33592199 | Life Sci | Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. | 2021 | Details |
| A04670 | 33546130 | Nutrients | Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A05240 | 33327438 | Int J Mol Sci | Natural Product Heme Oxygenase Inducers as Treatment for Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A05255 | 33321448 | Complement Ther Clin Pract | Efficacy of resveratrol supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. | 2020 | Details |
| A05329 | 33300526 | Food Funct | Improvement of the hepatic lipid status in intrauterine growth retarded pigs by resveratrol is related to the inhibition of mitochondrial dysfunction, oxidative stress and inflammation. | 2020 | Details |
| A05398 | 33271299 | Complement Ther Med | Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2020 | Details |
| A05695 | 33152943 | Biomed Pharmacother | The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. | 2020 | Details |
| A05709 | 33146212 | Food Funct | The influence of dietary conditions in the effects of resveratrol on hepatic steatosis. | 2020 | Details |
| A05798 | 33114299 | Antioxidants (Basel) | Comparative Effects of Pterostilbene and Its Parent Compound Resveratrol on Oxidative Stress and Inflammation in Steatohepatitis Induced by High-Fat High-Fructose Feeding. | 2020 | Details |
| A06105 | 33006712 | Mol Biol Rep | Low-dose trans-resveratrol induce poly(ADP)-ribosylation-dependent increase of the PPAR-γ protein expression level in the in vitro model of non-alcoholic fatty liver disease. | 2020 | Details |
| A06197 | 32971870 | Molecules | Urinary Resveratrol Metabolites Output: Differential Associations with Cardiometabolic Markers and Liver Enzymes in House-Dwelling Subjects Featuring Metabolic Syndrome. | 2020 | Details |
| A06365 | 32914125 | Curr Res Food Sci | Piceatannol attenuates fat accumulation and oxidative stress in steatosis-induced HepG2 cells. | 2020 | Details |
| A06487 | 32859881 | Chin J Physiol | Administration of low-dose resveratrol attenuated hepatic inflammation and lipid accumulation in high cholesterol-fructose diet-induced rat model of nonalcoholic fatty liver disease. | 2020 | Details |
| A06569 | 32823621 | Nutrients | Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease-A Meta-Analysis. | 2020 | Details |
| A06633 | 32800550 | Biochem Biophys Res Commun | Metformin, resveratrol, and exendin-4 inhibit high phosphate-induced vascular calcification via AMPK-RANKL signaling. | 2020 | Details |
| A06691 | 32779442 | Cell J | Nicotinamide Phosphoribosyltransferase Knockdown Leads to Lipid Accumulation in HepG2 Cells through The SIRT1-AMPK Pathway. | 2020 | Details |
| A06774 | 32751906 | Nutrients | Efficacy of Dietary Supplements to Reduce Liver Fat. | 2020 | Details |
| A06863 | 32718364 | Br J Nutr | Lactobacillus casei YRL577 combined with plant extracts reduce markers of non-alcoholic fatty liver disease in mice. | 2020 | Details |
| A07348 | 32529694 | Mol Nutr Food Res | Resveratrol Alleviates Endoplasmic Reticulum Stress-Associated Hepatic Steatosis and Injury in Mice Challenged with Tunicamycin. | 2020 | Details |
| A07576 | 32438122 | J Nutr Biochem | Resveratrol prevents liver damage in MCD-induced steatohepatitis mice by promoting SIGIRR gene transcription. | 2020 | Details |
| A07581 | 32436410 | Nutr Cancer | Combined Amelioration of Prebiotic Resveratrol and Probiotic Bifidobacteria on Obesity and Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A07667 | 32403305 | Antioxidants (Basel) | The Hepatoprotective Effect of Taurisolo, a Nutraceutical Enriched in Resveratrol and Polyphenols, Involves Activation of Mitochondrial Metabolism in Mice Liver. | 2020 | Details |
| A07697 | 32388250 | J Nutr Biochem | Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis. | 2020 | Details |
| A07708 | 32382557 | Biomed Res Int | A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix. | 2020 | Details |
| A07735 | 32371503 | BMJ Open Gastroenterol | SIRT1-dependent mechanisms and effects of resveratrol for amelioration of muscle wasting in NASH mice. | 2020 | Details |
| A07943 | 32303170 | Curr Pharm Des | Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease. | 2021 | Details |
| A07983 | 32290535 | Nutrients | Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases. | 2020 | Details |
| A08059 | 32265720 | Front Pharmacol | The Impacts of Herbal Medicines and Natural Products on Regulating the Hepatic Lipid Metabolism. | 2020 | Details |
| A08884 | 31953200 | J Ethnopharmacol | Study on the protection of water extracts of Polygoni Multiflori Radix and Polygoni Multiflori Radix Praeparata against NAFLD and its mechanism. | 2020 | Details |
| A09189 | 31842467 | Int J Mol Sci | Resveratrol Treatment Enhances the Cellular Response to Leptin by Increasing OBRb Content in Palmitate-Induced Steatotic HepG2 Cells. | 2019 | Details |
| A09200 | 31838177 | Int J Biochem Cell Biol | Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway. | 2019 | Details |
| A09257 | 31815784 | Curr Opin Endocrinol Diabetes Obes | Gastrointestinal peptides and nonalcoholic fatty liver disease. | 2020 | Details |
| A10432 | 31338065 | Front Endocrinol (Lausanne) | Resveratrol Reduces Glucolipid Metabolic Dysfunction and Learning and Memory Impairment in a NAFLD Rat Model: Involvement in Regulating the Imbalance of Nesfatin-1 Abundance and Copine 6 Expression. | 2019 | Details |
| A10485 | 31316594 | Exp Ther Med | Effect of resveratrol on non-alcoholic fatty liver disease. | 2019 | Details |
| A10695 | 31233775 | J Control Release | The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease. | 2019 | Details |
| A10795 | 31189495 | Clin Nutr | Resveratrol attenuates high-fat diet-induced non-alcoholic steatohepatitis by maintaining gut barrier integrity and inhibiting gut inflammation through regulation of the endocannabinoid system. | 2019 | Details |
| A10819 | 31173696 | Appl Physiol Nutr Metab | Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway. | 2019 | Details |
| A11252 | 30973211 | J Cell Mol Med | The phytochemical polydatin ameliorates non-alcoholic steatohepatitis by restoring lysosomal function and autophagic flux. | 2019 | Details |
| A11580 | 30832407 | Nutrients | Dietary Polyphenols Protect Against Oleic Acid-Induced Steatosis in an in Vitro Model of NAFLD by Modulating Lipid Metabolism and Improving Mitochondrial Function. | 2019 | Details |
| A11658 | 30800409 | R Soc Open Sci | Correction to 'Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy'. | 2019 | Details |
| A11692 | 30789808 | Int J Vitam Nutr Res | No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. | 2019 | Details |
| A11722 | 30776459 | Toxicology | Prenatal caffeine exposure increases the susceptibility to non-alcoholic fatty liver disease in female offspring rats via activation of GR-C/EBPα-SIRT1 pathway. | 2019 | Details |
| A11731 | 30773673 | Clin Exp Pharmacol Physiol | Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation. | 2019 | Details |
| A11937 | 30673851 | Med Mol Morphol | The therapeutic effects of resveratrol on hepatic steatosis in high-fat diet-induced obese mice by improving oxidative stress, inflammation and lipid-related gene transcriptional expression. | 2019 | Details |
| A12043 | 30625517 | Biomed Pharmacother | A novel resveratrol-curcumin hybrid, a19, attenuates high fat diet-induced nonalcoholic fatty liver disease. | 2019 | Details |
| A12119 | 32422008 | Crit Rev Eukaryot Gene Expr | Current Update on Preclinical and Clinical Studies of Resveratrol, a Naturally Occurring Phenolic Compound. | 2020 | Details |
| A12200 | 30564426 | R Soc Open Sci | Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy. | 2018 | Details |
| A12221 | 30557833 | Biomed Pharmacother | Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol. | 2018 | Details |
| A12264 | 30522586 | J Pharm Pharm Sci | Resveratrol Limits Lipogenesis and Enhance Mitochondrial Activity in HepG2 Cells. | 2018 | Details |
| A12276 | 30537742 | Cell Physiol Biochem | Resveratrol Ameliorates Lipid Droplet Accumulation in Liver Through a SIRT1/ ATF6-Dependent Mechanism. | 2018 | Details |
| A12797 | 30284135 | Dig Dis Sci | Resveratrol Improves Recovery and Survival of Diet-Induced Obese Mice Undergoing Extended Major (80%) Hepatectomy. | 2018 | Details |
| A12931 | 30221089 | PeerJ | Effects of resveratrol, exercises and their combination on Farnesoid X receptor, Liver X receptor and Sirtuin 1 gene expression and apoptosis in the liver of elderly rats with nonalcoholic fatty liver. | 2018 | Details |
| A12972 | 30201879 | Diseases | Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD. | 2018 | Details |
| A13089 | 30142943 | Nutrients | Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. | 2018 | Details |
| A13139 | 30120555 | Pflugers Arch | Catalase and nonalcoholic fatty liver disease. | 2018 | Details |
| A13145 | 30116360 | Exp Ther Med | 2,3,5,4'-tetrahydroxy-stilbene-2-O-β-D-glucoside attenuates methionine and choline-deficient diet-induced non-alcoholic fatty liver disease. | 2018 | Details |
| A13276 | 30055626 | Lipids Health Dis | Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system. | 2018 | Details |
| A13344 | 30023333 | Adv Pharm Bull | Effects of Pharmacologic Dose of Resveratrol Supplementation on Oxidative/Antioxidative Status Biomarkers in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. | 2018 | Details |
| A13403 | 29993072 | Food Funct | Involvement of autophagy in the beneficial effects of resveratrol in hepatic steatosis treatment. A comparison with energy restriction. | 2018 | Details |
| A13600 | 29885082 | Diabetes Obes Metab | No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease. | 2018 | Details |
| A13901 | 29702089 | Chem Biol Interact | Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase. | 2018 | Details |
| A14281 | 29484808 | Diabetes Obes Metab | Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial. | 2018 | Details |
| A14330 | 29463133 | Arch Physiol Biochem | Effects of combined therapy with resveratrol, continuous and interval exercises on apoptosis, oxidative stress, and inflammatory biomarkers in the liver of old rats with non-alcoholic fatty liver disease. | 2018 | Details |
| A14637 | 29313746 | J Am Coll Nutr | Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. | 2018 | Details |
| A14731 | 29268106 | J Nutr Biochem | Food components with antifibrotic activity and implications in prevention of liver disease. | 2017 | Details |
| A14948 | 29160087 | Antioxid Redox Signal | Glyoxalase 1 Modulation in Obesity and Diabetes. | 2018 | Details |
| A15084 | 29104641 | Exp Ther Med | Targeting Sirt1 in a rat model of high-fat diet-induced non-alcoholic fatty liver disease: Comparison of Gegen Qinlian decoction and resveratrol. | 2017 | Details |
| A15276 | 28989978 | NPJ Precis Oncol | The therapeutic potential of resveratrol: a review of clinical trials. | 2017 | Details |
| A15410 | 28925892 | Curr Pharm Des | Natural Active Compounds from Plant Food and Chinese Herbal Medicine for Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A15602 | 28817690 | PLoS One | Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats. | 2017 | Details |
| A15656 | 28777914 | Can J Physiol Pharmacol | Resveratrol improves high-fat diet induced fatty liver and insulin resistance by concomitantly inhibiting proteolytic cleavage of sterol regulatory element-binding proteins, free fatty acid oxidation, and intestinal triglyceride absorption. | 2017 | Details |